Nearly two months after a public meeting to discuss the direction of CBD laws, the FDA still has no answers for industry stakeholders. Across the pond, UK Members of Parliament are targeting companies that haven’t been submitting product samples for cannabis clinical trials. Also, the Cannabis Trades Association publicly disputes the CMC’s new product report. […]